Skip to main content
BookPhysio.in
BackConditions and Recovery

Chemotherapy-Induced Cardiotoxicity: Anthracyclines, Trastuzumab, and Ejection Fraction Limits

By BookPhysio.in Editorial Team•3 min read

In short

Cardioprotective oncology rehabilitation counters anthracycline and trastuzumab cardiotoxicity through global longitudinal strain tracking and submaximal interval aerobic training.

Clinical exercise physiologist monitoring continuous ECG telemetry and blood pressure in a breast cancer patient undergoing cardiotoxicity rehabilitation
In this guide (4 sections)

Topoisomerase II-Beta Cleavage and Myocardial Oxidative Stress

Cancer Therapeutics-Related Cardiac Dysfunction (CTRCD) is a major cause of non-cancer morbidity and mortality in long-term cancer survivors. Cardiotoxicity is broadly categorized into two distinct pathophysiological paradigms: Type 1 (irreversible cardiomyocyte necrosis) and Type 2 (reversible cellular dysfunction). Type 1 cardiotoxicity is exemplified by anthracyclines (doxorubicin, epirubicin). Anthracyclines inhibit topoisomerase II-beta in non-proliferating cardiomyocytes, triggering mitochondrial reactive oxygen species (ROS) cascades, iron accumulation, DNA double-strand breaks, and irreversible cardiomyocyte apoptosis with dose-dependent cumulative myocardial fibrosis.

Conversely, Type 2 cardiotoxicity is classically induced by the HER2-targeted monoclonal antibody trastuzumab. Blocking HER2/ErbB2 signaling in cardiomyocytes disrupts essential myocardial survival and repair pathways under stress, causing temporary sarcomeric uncoupling and left ventricular systolic dysfunction that typically lacks ultrastructural necrosis and resolves following drug cessation. If unrecognized, untreated CTRCD leads to refractory congestive heart failure with severely depressed left ventricular ejection fraction (LVEF).

Standardized Clinical Outcome Measures and Echocardiographic Staging

Echocardiographic and Biomarker Criteria for Oncology Cardiotoxicity
Cardiac Surveillance ModalityBaseline Normal FindingCardiotoxicity Diagnostic ThresholdExercise Rehabilitation Dosing Mandate
Left Ventricular Ejection Fraction (LVEF)Normal baseline LVEF 55% to 70%Drop in LVEF > 10 percentage points to < 50%HALT HIGH-INTENSITY EXERCISE; initiate ACE-inhibitor / beta-blocker
Global Longitudinal Strain (GLS)Normal GLS more negative than -18% (e.g. -20%)Relative percentage drop > 15% from baselineEARLIEST MARKER: Detects subclinical myocardial strain before LVEF drops
Serum High-Sensitivity Troponin I / TUndetectable or within normal reference limitsPersistent elevation above 99th percentileIndicates active ongoing cardiomyocyte membrane breakdown
Resting Heart Rate / Peak VO2Resting HR 60-80 bpm; normal age-matched VO2 peakResting HR > 100 bpm (inappropriate sinus tachycardia)Submaximal aerobic interval exercise capped at 60% of VO2 reserve
New York Heart Association (NYHA)Class I (no limitation in ordinary physical activity)Class II/III (fatigue, palpitations, or dyspnea on walking)Structured phase 2 cardiac rehabilitation; avoid sudden isometric loads

Standardized Clinical Rehabilitation Protocols and Cardiac Safety

  • Proactive Submaximal Interval Aerobic Conditioning: Prescribe 20 to 30 minutes of low-to-moderate intensity interval cycling or walking (40% to 60% of heart rate reserve) 3 times weekly during anthracycline and trastuzumab therapy; exercise stimulates endothelial nitric oxide production, reduces systemic vascular resistance, and prevents chemotherapy-induced myocardial remodeling.
  • Strict Avoidance of Heavy Isometric Straining (Valsalva): Prohibit heavy resistance leg presses and breath-holding; sustained isometric contraction drastically spikes mean arterial pressure and left ventricular afterload, predisposing to acute pulmonary edema in patients with borderline ejection fractions.
  • Monitoring for Overt Congestive Heart Failure Red Flags: Weigh the patient weekly and inspect the lower extremities; sudden unexplained weight gain (> 2 kg in 3 days), bilateral dependent pitting ankle edema, or orthopnea (needing extra pillows to sleep) mandates immediate cardiology referral.

Frequently Asked Questions

How can chemotherapy harm the heart and why does my doctor order heart scans?

Certain powerful cancer medicines (like doxorubicin or Herceptin) can stress or weaken heart muscle cells while destroying cancer cells. Getting an echocardiogram every few months allows doctors to spot early changes in heart pumping power long before you feel out of breath, allowing heart-protective medications to be started early.

Can exercise protect my heart while I am receiving chemotherapy?

Yes! Clinical studies show that regular, gentle aerobic exercise (like riding a stationary bicycle or walking) helps protect heart muscle fibers from chemotherapy damage, improves blood flow, and keeps your heart strong during cancer treatment.

What heart symptoms should make me stop exercising immediately?

Stop exercising right away and call your doctor if you feel sudden chest tightness, irregular fluttering heartbeats, extreme shortness of breath, sudden lightheadedness, or if you wake up gasping for air when lying flat in bed.

Clinical SpecialtyOncology Physiotherapy
Explore Oncology specialty guides →

Related condition guides

BookPhysio.in Editorial Team

The BookPhysio.in editorial team writes and maintains this content, checking it against reliable clinical sources. Content follows our medical review policy: general information only, and no page claims a clinical review until a named registered physiotherapist has signed it off.

Read our medical review policy

Was this page helpful?